95 related articles for article (PubMed ID: 29017786)
1. Identification of novel PI3K inhibitors through a scaffold hopping strategy.
Martínez González S; Hernández AI; Álvarez RM; Rodríguez A; Ramos-Lima F; Bischoff JR; Albarrán MI; Cebriá A; Hernández-Encinas E; García-Arocha J; Cebrián D; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2017 Nov; 27(21):4794-4799. PubMed ID: 29017786
[TBL] [Abstract][Full Text] [Related]
2. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
[TBL] [Abstract][Full Text] [Related]
3. Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.
Martínez González S; Rodríguez-Arístegui S; Hernández AI; Varela C; González Cantalapiedra E; Álvarez RM; Rodríguez Hergueta A; Bischoff JR; Albarrán MI; Cebriá A; Cendón E; Cebrián D; Alfonso P; Pastor J
Bioorg Med Chem Lett; 2017 Jun; 27(11):2536-2543. PubMed ID: 28404374
[TBL] [Abstract][Full Text] [Related]
4. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase.
Mortensen DS; Sapienza J; Lee BG; Perrin-Ninkovic SM; Harris R; Shevlin G; Parnes JS; Whitefield B; Hickman M; Khambatta G; Bisonette RR; Peng S; Gamez JC; Leisten J; Narla RK; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2013 Mar; 23(6):1588-91. PubMed ID: 23414803
[TBL] [Abstract][Full Text] [Related]
5. Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Alvarez RM; García AB; Lorenzo M; Rivero V; Oyarzabal J; Rabal O; Bischoff JR; Albarrán M; Cebriá A; Alfonso P; Link W; Fominaya J; Pastor J
Bioorg Med Chem Lett; 2012 Mar; 22(5):1874-8. PubMed ID: 22325943
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
[TBL] [Abstract][Full Text] [Related]
7. Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Lorenzo M; Rodríguez A; Rivero V; Martín JI; Saluste CG; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán M; Alfonso P; García-Serelde B; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Pastor J
Bioorg Med Chem Lett; 2012 May; 22(10):3460-6. PubMed ID: 22520259
[TBL] [Abstract][Full Text] [Related]
8. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of pyrrolotriazine based molecules as PI3 kinase inhibitors.
Dugar S; Hollinger FP; Kuila B; Arora R; Sen S; Mahajan D
Bioorg Med Chem Lett; 2015 Aug; 25(16):3142-6. PubMed ID: 26112437
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-3-kinase inhibitors: evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511.
Lanman BA; Reed AB; Cee VJ; Hong FT; Pettus LH; Wurz RP; Andrews KL; Jiang J; McCarter JD; Mullady EL; San Miguel T; Subramanian R; Wang L; Whittington DA; Wu T; Zalameda L; Zhang N; Tasker AS; Hughes PE; Norman MH
Bioorg Med Chem Lett; 2014 Dec; 24(24):5630-5634. PubMed ID: 25466188
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.
Saidel MÉ; Dos Santos KC; Nagano LFP; Montanari CA; Leitão A
Bioorg Med Chem Lett; 2017 Sep; 27(17):4001-4006. PubMed ID: 28774426
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
[TBL] [Abstract][Full Text] [Related]
13. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
15. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
Li H; Jin X; Zhang Z; Xing Y; Kong X
Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
[TBL] [Abstract][Full Text] [Related]
17. Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.
Liu KK; Bailey S; Dinh DM; Lam H; Li C; Wells PA; Yin MJ; Zou A
Bioorg Med Chem Lett; 2012 Aug; 22(15):5114-7. PubMed ID: 22765900
[TBL] [Abstract][Full Text] [Related]
18. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; Corchete LA; San Miguel JF; Del Cañizo C; Blanco B
J Hematol Oncol; 2016 Oct; 9(1):113. PubMed ID: 27765055
[TBL] [Abstract][Full Text] [Related]
19. Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Belanger DB; Curran PJ; Hruza A; Voigt J; Meng Z; Mandal AK; Siddiqui MA; Basso AD; Gray K
Bioorg Med Chem Lett; 2010 Sep; 20(17):5170-4. PubMed ID: 20674350
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
